Processa Pharmaceuticals, Inc. Business Combination, Consideration Transferred
Processa Pharmaceuticals, Inc. (PCSA) reported Business Combination, Consideration Transferred of $8.00 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-14.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationConsiderationTransferred1 · last filed 2019-08-14
- Processa Pharmaceuticals, Inc. business combination, consideration transferred for the quarter ending 2019-06-30 was $0.00.
- Processa Pharmaceuticals, Inc. business combination, consideration transferred for the quarter ending 2019-03-31 was $8.00M.
- Processa Pharmaceuticals, Inc. business combination, consideration transferred for fiscal 2018 was $8.00M.
| Period end | Business Combination, Consideration Transferred 3 month | Business Combination, Consideration Transferred 6 month | Business Combination, Consideration Transferred 12 month |
|---|---|---|---|
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $8.00M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $8.00M 10-Q · filed 2019-05-14 | ||
| 2018-12-31 | $8.00M 10-K/A · filed 2019-04-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |